|
1.
|
Gillison ML, Koch WM, Capone RB, Spafford
M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE,
Shah KV and Sidransky D: Evidence for a causal association between
human papillomavirus and a subset of head and neck cancers. J Natl
Cancer Inst. 92:709–720. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Mellin H, Friesland S, Lewensohn R,
Dalianis T and Munck-Wikland E: Human papillomavirus (HPV) DNA in
tonsillar cancer: clinical correlates, risk of relapse, and
survival. Int J Cancer. 89:300–304. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Dahlstrand HM and Dalianis T: Presence and
influence of human papillomaviruses (HPV) in tonsillar cancer. Adv
Cancer Res. 93:59–89. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
WHO: IARC Monographs on the Evaluation of
Carcinogenic Risk to Humans. International Agency for Research on
Cancer; Lyon: 2007
|
|
5.
|
Robinson KL and Macfarlane GJ:
Oropharyngeal cancer incidence and mortality in Scotland: are rates
still increasing? Oral Oncol. 39:31–36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Hammarstedt L, Lindquist D, Dahlstrand H,
Romanitan M, Dahlgren LO, Joneberg J, Creson N, Lindholm J, Ye W,
Dalianis T and Munck-Wikland E: Human papillomavirus as a risk
factor for the increase in incidence of tonsillar cancer. Int J
Cancer. 119:2620–2623. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Conway DI, Stockton DL, Warnakulasuriya
KA, Ogden G and Macpherson LM: Incidence of oral and oropharyngeal
cancer in United Kingdom (1990–1999) - recent trends and regional
variation. Oral Oncol. 42:586–592. 2006.PubMed/NCBI
|
|
8.
|
Hammarstedt L, Dahlstrand H, Lindquist D,
Onelöv L, Ryott M, Luo J, Dalianis T, Ye W and Munck-Wikland E: The
incidence of tonsillar cancer in Sweden is increasing. Acta
Otolaryngol. 1279:988–992. 2007. View Article : Google Scholar
|
|
9.
|
Sturgis EM and Cinciripini PM: Trends in
head and neck cancer incidence in relation to smoking prevalence:
an emerging epidemic of human papillomavirus-associated cancers?
Cancer. 110:1429–1435. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Chaturvedi AK, Engels EA, Anderson WF and
Gillison ML: Incidence trends for human papillomavirus-related and
-unrelated oral squamous cell carcinomas in the United States. J
Clin Oncol. 26:612–619. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Nasman A, Attner P, Hammarstedt L, Du J,
Eriksson M, Giraud G, Sparén P, Ye W, Dahlstrand H, Munck-Wikland E
and Dalianis T: Incidence of human papillomavirus (HPV) positive
tonsillar carcinoma in Stockholm, Sweden: an epidemic of
viral-induced carcinoma? Int J Cancer. 125:362–366. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Braakhuis BJ, Visser O and Leemans CR:
Oral and oropharyngeal cancer in The Netherlands between 1989 and
2006: increasing incidence, but not in young adults. Oral Oncol.
45:e85–e89. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Attner P, Du J, Nasman A, Hammarstedt L,
Ramqvist T, Lindholm J, Marklund L, Dalianis T and Munck-Wikland E:
The role of human papillomavirus in the increased incidence of base
of tongue cancer. Int J Cancer. 126:2879–2884. 2010.PubMed/NCBI
|
|
14.
|
Marur S, D’Souza G, Westra WH and
Forastiere AA: HPV-associated head and neck cancer: a virus-related
cancer epidemic. Lancet Oncol. 11:781–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Ramqvist T and Dalianis T: Oropharyngeal
epidemic and human papillomavirus. Emerg Infect Dis. 16:1671–1677.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Ramqvist T and Dalianis T: An epidemic of
oropharyngeal squamous cell carcinoma (OSCC) due to human
papilloma-virus (HPV) infection and aspects of treatment and
prevention. Anticancer Res. 31:1515–1519. 2011.PubMed/NCBI
|
|
17.
|
Chaturvedi AK, Engels EA, Pfeiffer RM,
Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M,
Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S,
Anderson WF, Rosenberg PS and Gillison ML: Human papillomavirus and
rising oropharyngeal cancer incidence in the United States. J Clin
Oncol. 29:4294–4301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Lindquist D, Romanitan M, Hammarstedt L,
Nasman A, Dahlstrand H, Lindholm J, Onelöv L, Ramqvist T, Ye W,
Munck-Wikland E and Dalianis T: Human papillomavirus is a
favourable prognostic factor in tonsillar cancer and its oncogenic
role is supported by the expression of E6 and E7. Mol Oncol.
1:350–355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Attner P, Du J, Näsman A, Hammarstedt L,
Ramqvist T, Lindholm J, Marklund L, Dalianis T and Munck-Wikland E:
Human papillomavirus and survival in patients with base of tongue
cancer. Int J Cancer. 128:2892–2897. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Licitra L, Bernier J, Grandi C, Merlano M,
Bruzzi P and Lefebvre JL: Cancer of the oropharynx. Crit Rev Oncol
Hematol. 41:107–122. 2002. View Article : Google Scholar
|
|
21.
|
Tommasino M: The human papillomavirus
family and carcinogenesis. Semin Cancer Biol. Dec 4–2013.(Epub
ahead of print). pii: S1044-579X(13)00123-5. View Article : Google Scholar
|
|
22.
|
Zur Hausen H: Papillomavirus infections: a
major cause of human cancer. Infections Causing Human Cancer.
Wiley-VCH Verlag; Weinheim: pp. 145–243. 2006, PubMed/NCBI
|
|
23.
|
Oguejiofor KK, Hall JS, Mani N, Douglas C,
Slevin NJ, Homer J, Hall G and West CM: The prognostic significance
of the biomarker p16 in oropharyngeal squamous cell carcinoma. Clin
Oncol (R Coll Radiol). 25:630–638. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Paavonen J, Jenkins D, Bosch FX, Naud P,
Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC,
Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA,
Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P,
Struyf F, Wieting SL, Lehtinen MO and Dubin G: HPV PATRICIA study
group: Efficacy of a prophylactic adjuvanted bivalent L1
virus-like-particle vaccine against infection with human
papillomavirus types 16 and 18 in young women: an interim analysis
of a phase III double-blind, randomised controlled trial. Lancet.
369:2161–2170. 2007. View Article : Google Scholar
|
|
25.
|
Future II Study Group: Qvadrivalent
vaccine against human papillomavirus to prevent high-graded
cervical lesions. N Engl J Med. 356:1915–1927. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Ramqvist T, Andreasson K and Dalianis T:
Vaccination, immune and gene therapy based on virus-like particles
against viral infections and cancer. Expert Opin Biol Ther.
7:997–1007. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Dalianis T: Immunotherapy for
polyomaviruses: opportunities and challenges. Immunotherapy.
4:617–628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Mellin H, Dahlgren L, Munck-Wikland E,
Lindholm J, Rabbani H, Kalantari M and Dalianis T: Human
papillomavirus type 16 is episomal and a high viral load may be
correlated to better prognosis in tonsillar cancer. Int J Cancer.
102:152–158. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Koskinen WJ, Chen RW, Leivo I, Mäkitie A,
Bäck L, Kontio R, Suuronen R, Lindqvist C, Auvinen E, Molijn A,
Quint WG, Vaheri A and Aaltonen LM: Prevalence and physical status
of human papillomavirus in squamous cell carcinomas of the head and
neck. Int J Cancer. 107:401–406. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Mellin Dahlstrand H, Lindquist D,
Bjornestal L, Ohlsson A, Dalianis T, Munck-Wikland E and Elmberger
G: P16(INK4a) correlates to human papillomavirus presence, response
to radio-therapy and clinical outcome in tonsillar carcinoma.
Anticancer Res. 25:4375–4383. 2005.PubMed/NCBI
|
|
31.
|
Mellin H, Friesland S, Auer G, Dalianis T
and Munck-Wikland E: Human papillomavirus and DNA ploidy in
tonsillar cancer -correlation to prognosis. Anticancer Res.
23:2821–2828. 2003.PubMed/NCBI
|
|
32.
|
Dahlgren L, Mellin H, Wangsa D,
Heselmeyer-Haddad K, Björnestål L, Lindholm J, Munck-Wikland E,
Auer G, Ried T and Dalianis T: Comparative genomic hybridization
analysis of tonsillar cancer reveals a different pattern of genomic
imbalances in human papillomavirus-positive and -negative tumors.
Int J Cancer. 107:244–249. 2003. View Article : Google Scholar
|
|
33.
|
Ang KK, Harris J, Wheeler R, Weber R,
Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C,
Kim H, Axelrod R, Silverman CC, Redmond KP and Gillison ML: Human
papillomavirus and survival of patients with oropharyngeal cancer.
N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
de Roda Husman AM, Walboomers JM, van den
Brule AJ, Meijer CJ and Snijders PJ: The use of general primers GP5
and GP6 elongated at their 3’ ends with adjacent highly conserved
sequences improves human papillomavirus detection by PCR. J Gen
Virol. 76:1057–1062. 1995.
|
|
35.
|
Tieben LM, ter Schegget J, Minnaar RP,
Bouwes Bavinck JN, Berkhout RJ, Vermeer BJ, Jebbink MF and Smits
HL: Detection of cutaneous and genital HPV types in clinical
samples by PCR using consensus primers. J Virol Methods.
42:265–279. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
van den Brule AJ, Pol R,
Fransen-Daalmeijer N, Schouls LM, Meijer CJ and Snijders PJ:
GP5+/6+ PCR followed by reverse line blot
analysis enables rapid and high-throughput identification of human
papillomavirus genotypes. J Clin Microbiol. 40:779–787. 2002.
|
|
37.
|
Clavel C, Masure M, Bory JP, Putaud I,
Mangeonjean C, Lorenzato M, Gabriel R and Quereux C: Hybrid Capture
II-based human papillomavirus detection, a sensitive test to detect
in routine high-grade cervical lesions: a preliminary study on 1518
women. Br J Cancer. 80:1306–1311. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Gravitt PE, Peyton CL, Apple RJ and
Wheeler CM: Genotyping of 27 human papillomavirus types by using L1
consensus PCR products by a single-hybridization, reverse line blot
detection method. J Clin Microbiol. 36:3020–3027. 1998.
|
|
39.
|
Schmitt M, Bravo IG, Snijders PJ, Gissmann
L, Pawlita M and Waterboer T: Bead-based multiplex genotyping of
human papillomaviruses. J Clin Microbiol. 44:504–512. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Smeets SJ, Hesselink AT, Speel EJ,
Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ,
Leemans CR and Brakenhoff RH: A novel algorithm for reliable
detection of human papillomavirus in paraffin-embedded head and
neck cancer specimen. Int J Cancer. 121:2465–2472. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Marklund L, Näsman A, Ramqvist T, Dalianis
T, Munck-Wikland E and Hammarstedt L: Prevalence of human
papillomavirus and survival in oropharyngeal cancer other than
tonsil or base of tongue cancer. Cancer Med. 1:82–88. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Anaya-Saavedra G, Ramirez-Amador V,
Irigoyen-Camacho ME, Garcia-Cuellar CM, Guido-Jimenez M,
Mendez-Martinez R and García-Carrancá A: High association of human
papillomavirus infection with oral cancer: a case-control study.
Arch Med Res. 39:189–197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
D’Souza G, Agrawal Y, Halpern J, Bodison S
and Gillison ML: Oral sexual behaviors associated with prevalent
oral human papillomavirus infection. J Infect Dis. 199:1263–1269.
2009.PubMed/NCBI
|
|
44.
|
Syrjänen S and Puranen M: Human
papillomavirus infections in children: the potential role of
maternal transmission. Crit Rev Oral Biol Med. 11:259–274.
2000.PubMed/NCBI
|
|
45.
|
Näsman A, Andersson E, Nordfors C, Grün N,
Johansson H, Munck-Wikland E, Massucci G, Dalianis T and Ramqvist
T: MHC class I expression in HPV positive and negative tonsillar
squamous cell carcinoma in correlation to clinical outcome. Int J
Cancer. 132:72–81. 2013.PubMed/NCBI
|
|
46.
|
Näsman A, Andersson E, Marklund L,
Tertipis N, Hammarstedt-Nordenwall L, Nyberg T, Munck-Wikland E,
Masucci GV, Ramqvist T and Dalianis T: HLA class I and II
expression in oropharyngeal squamous cell carcinoma in relation to
tumor HPV status and clinical outcome. PloS One.
8:e77025432013.PubMed/NCBI
|
|
47.
|
Lindquist D, Ahrlund-Richter A, Tarján M,
Tot T and Dalianis T: Intense CD44 expression is a negative
prognostic factor in tonsillar and base of tongue cancer.
Anticancer Res. 32:153–161. 2012.PubMed/NCBI
|
|
48.
|
Näsman A, Nordfors C, Grün N,
Munck-Wikland E, Ramqvist T, Marklund L, Lindquist D and Dalianis
T: Absent/weak CD44 intensity and positive human papillomavirus
(HPV) status in oropharyngeal squamous cell carcinoma indicates a
very high survival. Cancer Med. 2:507–518. 2013.PubMed/NCBI
|
|
49.
|
Rietbergen MM, Martens-de Kemp SR,
Bloemena E, Witte BI, Brink A, Baatenburg de Jong RJ, Leemans CR,
Braakhuis BJ and Brakenhoff RH: Cancer stem cell enrichment marker
CD98: A prognostic factor for survival in patients with human
papillomavirus-positive oropharyngeal cancer. Eur J Cancer. Dec
4–2013.(Epub ahead of print). pii: S0959-8049(13)01005-8.
View Article : Google Scholar
|
|
50.
|
Näsman A, Romanitan M, Nordfors C, Grün N,
Johansson H, Hammarstedt L, Marklund L, Munck-Wikland E, Dalianis T
and Ramqvist T: Tumor infiltrating CD8+ and Foxp3+
lymphocytes correlate to clinical outcome and human papillomavirus
(HPV) status in tonsillar cancer. PLoS One. 7:e387112012.
|
|
51.
|
Nordfors C, Grün N, Tertipis N,
Ahrlund-Richter A, Haeggblom L, Sivars L, Du J, Nyberg T, Marklund
L, Munck-Wikland E, Näsman A, Ramqvist T and Dalianis T: CD8(+) and
CD4(+) tumour infiltrating lymphocytes in relation to human
papillomavirus status and clinical outcome in tonsillar and base of
tongue squamous cell carcinoma. Eur J Cancer. 49:2522–2530.
2013.
|
|
52.
|
Spanos WC, Nowicki P, Lee DW, Hoover A,
Hostager B, Gupta A, Anderson ME and Lee JH: Immune response during
therapy with cisplatin or radiation for human
papillomavirus-related head and neck cancer. Arch Otolaryngol Head
Neck Surg. 135:1137–1146. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Lajer CB, Garnæs E, Friis-Hansen L,
Norrild B, Therkildsen MH, Glud M, Rossing M, Lajer H, Svane D,
Skotte L, Specht L, Buchwald C and Nielsen FC: The role of miRNAs
in human papilloma virus (HPV)-associated cancers: bridging between
HPV-related head and neck cancer and cervical cancer. Br J Cancer.
106:1526–1534. 2012. View Article : Google Scholar
|
|
54.
|
Kreimer AR, Bhatia RK, Messeguer AL,
Gonzalez P, Herrero R and Giuliano AR: Oral human papillomavirus in
healthy individuals: a systematic review of the literature. Sex
Transm Dis. 37:386–391. 2010.
|
|
55.
|
Rautava J and Syrjanen S: Human
papillomavirus infections in the oral mucosa. J Am Dent Assoc.
142:905–914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Du J, Nordfors C, Ahrlund-Richter A,
Sobkowiak M, Romanitan M, Näsman A, Andersson S, Ramqvist T and
Dalianis T: Prevalence of oral human papillomavirus infection among
youth, Sweden. Emerg Infect Dis. 18:1468–1471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Nordfors C, Grün N, Haeggblom L, Tertipis
N, Sivars L, Mattebo M, Larsson M, Häggström-Nordin E, Tydén T,
Ramqvist T and Dalianis T: Oral human papillomavirus prevalence in
high school students of one municipality in Sweden. Scand J Infect
Dis. 45:878–881. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Steinau M, Hariri S, Gillison ML, Broutian
TR, Dunne EF, Tong ZY, Markowitz LE and Unger ER: Cervical and oral
HPV prevalence among females in the United States. J Infect Dis.
Jan 10–2014.(Epub ahead of print).
|
|
59.
|
D’Souza G, Kreimer AR, Viscidi R, Pawlita
M, Fakhry C, Koch WM, Westra WH and Gillison ML: Case-control study
of human papillomavirus and oropharyngeal cancer. N Engl J Med.
356:1944–1956. 2007.PubMed/NCBI
|
|
60.
|
Fakhry C, Rosenthal BT, Clark DP and
Gillison ML: Associations between oral HPV16 infection and
cytopathology: evaluation of an oropharyngeal ‘pap-test equivalent’
in high-risk populations. Cancer Prev Res. 4:1378–1384.
2011.PubMed/NCBI
|
|
61.
|
Herrero R, Quint W, Hildesheim A, Gonzalez
P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC,
Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ and
Wacholder S: Reduced prevalence of oral human papillomavirus (HPV)
4 years after bivalent HPV vaccination in a randomized clinical
trial in Costa Rica. PLoS One. 8:e683292013.PubMed/NCBI
|
